Journal article
RDP58 is a novel and potentially effective oral therapy for ulcerative colitis.
- Abstract:
-
BACKGROUND: RDP58 is a novel anti-inflammatory d-amino acid decapeptide that inhibits synthesis of proinflammatory cytokines by disrupting cell signaling at the pre-MAPK MyD88-IRAK-TRAF6 protein complex. We therefore evaluated its efficacy and safety in parallel multicenter, double-blind, randomized concept studies in ulcerative colitis (UC). METHODS: In the first trial, 34 patients with mild to moderate active UC were randomized (1:2) to placebo (n = 13) or RDP58 100 mg (n = 21). In the sec...
Expand abstract
- Publication status:
- Published
Actions
Authors
Bibliographic Details
- Journal:
- Inflammatory bowel diseases
- Volume:
- 11
- Issue:
- 8
- Pages:
- 713-719
- Publication date:
- 2005-08-01
- DOI:
- EISSN:
-
1536-4844
- ISSN:
-
1078-0998
- Source identifiers:
-
111485
Item Description
- Language:
- English
- Keywords:
- Pubs id:
-
pubs:111485
- UUID:
-
uuid:c8eaca4b-0bd3-498c-85bb-dcd26ce215a7
- Local pid:
- pubs:111485
- Deposit date:
- 2012-12-19
Terms of use
- Copyright date:
- 2005
If you are the owner of this record, you can report an update to it here: Report update to this record